Alnylam closes $1.035B convertible note offering; repays $762M credit facility

ALNYLAM PHARMACEUTICALS, INC.

Issued $1.035B aggregate principal of 1.00% Convertible Senior Notes due 2027 (initial $900M plus $135M additional).
Conversion rate initially 3.4941 shares per $1,000 principal; conversion price ~$286.20/share, a 35% premium over $212 closing.
Entered capped call transactions with cap price $424/share; cost ~$118.6M to reduce dilution upon conversion.
Used ~$762M of proceeds to repay and terminate April 2020 credit agreement.
Notes mature Sept 15, 2027; interest payable semiannually at 1.00%.

item 1.01 item 1.02 item 2.03 item 3.02 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.